title: Non-canonical modulators of nuclear receptors.
abstract: Like G protein-coupled receptors (GPCRs) and protein kinases, nuclear receptors (NRs) are a rich source of pharmaceutical targets. Over 80 NR-targeting drugs have been approved for 18 NRs. The focus of drug discovery in NRs has hitherto been on identifying ligands that bind to the canonical ligand binding pockets of the C-terminal ligand binding domains (LBDs). Due to the development of drug resistance and selectivity concerns, there has been considerable interest in exploring other, non-canonical ligand binding sites. Unfortunately, the potencies of compounds binding at other sites have generally not been sufficient for clinical development. However, the situation has changed dramatically over the last 3years, as compounds with sufficient potency have been reported for several NR targets. Here we review recent developments in this area from a medicinal chemistry point of view in the hope of stimulating further interest in this area of research.
authors: Vitae Pharmaceuticals, Inc., 502 West Office Center Drive, Fort Washington, PA 19034, United States.
authors: Colin M
authors: CM
authors: Tice
authors: Vitae Pharmaceuticals, Inc., 502 West Office Center Drive, Fort Washington, PA 19034, United States.
authors: Ya-Jun
authors: YJ
authors: Zheng
mesh_terms: D000494:Allosteric Regulation; D001665:Binding Sites; D002626:Chemistry, Pharmaceutical; D015195:Drug Design; D006801:Humans; D008024:Ligands; D062105:Molecular Docking Simulation; D000072417:Protein Domains; D018160:Receptors, Cytoplasmic and Nuclear / Q000737:chemistry / Q000378:metabolism*
chemical_list: D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear
keywords: Agonist; Allosteric; Antagonist; Drug discovery; Non-canonical; Nuclear receptor